SHANK3 HAPLOINSUFFICIENCY

Clinical trials for SHANK3 HAPLOINSUFFICIENCY explained in plain language.

Never miss a new study

Get alerted when new SHANK3 HAPLOINSUFFICIENCY trials appear

Sign up with your email to follow new studies for SHANK3 HAPLOINSUFFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

First human trial tests One-Shot gene therapy for rare genetic disorder

Disease control Recruiting now

This early-stage study is testing a single dose of an experimental gene therapy called JAG201 in children aged 2-9 with SHANK3 deficiency, which causes Phelan-McDermid Syndrome. The main goal is to check if the treatment is safe and tolerable when injected into the fluid around t…

Matched conditions: SHANK3 HAPLOINSUFFICIENCY

Phase: PHASE1, PHASE2 • Sponsor: Jaguar Gene Therapy, LLC • Aim: Disease control

Last updated Apr 23, 2026 10:29 UTC

SHANK3 HAPLOINSUFFICIENCY

Get alerted when new SHANK3 HAPLOINSUFFICIENCY trials appear

First human trial tests One-Shot gene therapy for rare genetic disorder